ClinicalTrials.gg
CompletedNCT00685906Updated Dec 2, 2010

AZD6140 Oral Contraceptive Interaction Study

A Phase 1 interventional study of AZD6140 and Levonorgestrel and Ethinyl Estradiol (Nordette®) in Healthy, sponsored by AstraZeneca. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-12-02.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The purpose of this study is to examine the effect of co-administration of AZD6140 and Nordette® on the blood levels of certain female hormones.

02

Conditions studied

  • Healthy

Keywords

  • oral contraceptive
  • birth control
  • Healthy volunteers
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females who are healthy, non-pregnant, not planning pregnancy within the study period, non-breast-feeding, and pre-menopausal
  • Either currently taking Nordette® which was well tolerated for at least two months prior to randomisation with no history of break-through bleeding, or, willing to take Nordette for 2 months prior to receiving the study drug
  • Females of must be willing to use at least 1 additional medically approved non-hormonal barrier method (for example, condom or diaphragm) that contains spermicide

Exclusion criteria

Exclusion Criteria:

  • History of intolerance (e.g. adverse events) to any oral or AZD6140
  • History of blood vessel or bleeding conditions that would make the volunteer more prone to bleeding
  • History or presence of significant medical problems
  • Women who are current smokers
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    1

    Drug: AZD6140

  • Active comparator
    2

    Drug: Levonorgestrel and Ethinyl Estradiol (Nordette®)

Interventions

  • 90 mg tablet taken by mouth 2 times a day for 21 days per cycle

  • DrugLevonorgestrel and Ethinyl Estradiol (Nordette®)

    Drug page: Ethinyl Estradiol-Norgestrel Combination

    1 tablet taken by mouth once a day for 28 days per cycle

    Also known as: Nordette®

06

What researchers measure

Primary outcomes

  1. Blood levels of ethinyl estradiol, a female hormone, following oral administration of AZD6140 and Nordette®

    Time frame: At scheduled times following dosing during the first 3 weeks of menstrual cycles 1 and 2.

Secondary outcomes

  1. Blood levels of various other hormones following concomitant oral administration of AZD6140 and Nordette®

    Time frame: At scheduled times following dosing during the first 3 weeks of menstrual cycles 1 and 2.

  2. Blood levels of AZD6140 and its main metabolite after concomitant oral administration of AZD6140 and Nordette®

    Time frame: At scheduled times following dosing during the first 3 weeks of Cycles 1 and 2.

  3. Safety and tolerability of AZD6140 when co-administered with Nordette®

    Time frame: Screening through completion of the study

07

Study locations

1 site
  • Research Site
    Miami, Florida, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2008
First posted
May 29, 2008
Start
Apr 2008
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Last update
Dec 2, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00685906
Lead sponsor
AstraZeneca
First posted
May 29, 2008
Start date
Apr 2008
Primary completion
Oct 2008
Completion
Oct 2008
Last update
Dec 2, 2010

Study contacts

Kathleen Butler, MD
study director · AstraZeneca
Audrey, Martinez, MD
principal investigator · SeaView Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ticagrelor · Ethinyl Estradiol-Norgestrel Combination

Start the discussion